Sun Pharma Advanced Research Company (NSE:SPARC, BOM:532872) and CMS Bridging DMCC have mutually terminated their license agreement without providing a reason, according to a Friday filing with the Indian stock exchanges.
The license agreement entails developing and commercializing multiple products, including Xelpros, Elepsia, Taclantis, PDP-716, and SDN-037, in Mainland China, Hong Kong, Macao, and Taiwan.
Sun Pharma said the termination is not expected to have any material impact on the company's financial position, operations, or other activities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments